News headlines about Digirad (NASDAQ:DRAD) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Digirad earned a coverage optimism score of 0.06 on Accern’s scale. Accern also gave media stories about the medical equipment provider an impact score of 46.1612211840934 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Separately, ValuEngine cut shares of Digirad from a “buy” rating to a “hold” rating in a research report on Wednesday, May 2nd.
Shares of DRAD traded down $0.02 during mid-day trading on Friday, reaching $1.68. The stock had a trading volume of 38,872 shares, compared to its average volume of 41,650. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.62 and a quick ratio of 1.20. Digirad has a 52-week low of $1.25 and a 52-week high of $4.45.
The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 30th. Investors of record on Tuesday, May 15th were issued a $0.055 dividend. This represents a $0.22 dividend on an annualized basis and a dividend yield of 13.13%. The ex-dividend date was Monday, May 14th.
Digirad Corporation provides healthcare solutions in the United States. It operates through Diagnostic Services, Mobile Healthcare, and Diagnostic Imaging segments. The Diagnostic Services segment provides nuclear and ultrasound imaging services to physicians who perform nuclear imaging, echocardiography, vascular or general ultrasound tests, imaging systems, radiopharmaceuticals, and licensing services, as well as offers remote cardiac event monitoring services.
Receive News & Ratings for Digirad Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Digirad and related companies with MarketBeat.com's FREE daily email newsletter.